Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

viatris limited - tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245mg - film coated tablet - 300 mg - active: tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245mg excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 32k505018 - tenofovir disoproxil mylan is indicated for the treatment of chronic hepatitis b in adults and paediatric patients 12 years of age and older.

Ирландия - английский - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - tenofovir disoproxil fumarate - film-coated tablet - 245 milligram(s) - tenofovir disoproxil

Европейский союз - английский - EMA (European Medicines Agency)

krka, d.d., novo mesto - emtricitabine, tenofovir disoproxil succinate - hiv infections - antivirals for systemic use - treatment of hiv-1 infectionemtricitabine/tenofovir disoproxil krka is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults.emtricitabine/tenofovir disoproxil krka is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years (see section 5.1pre-exposure prophylaxis (prep)emtricitabine/tenofovir disoproxil krka is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults at high risk.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - tenofovir disoproxil succinate 300.6mg equivalent to tenofovir disoproxil 245 mg;   - film coated tablet - 245 mg - active: tenofovir disoproxil succinate 300.6mg equivalent to tenofovir disoproxil 245 mg   excipient: croscarmellose sodium indigo carmine aluminium lake lactose macrogol 3350 magnesium stearate microcrystalline cellulose polyvinyl alcohol pregelatinised maize starch purified talc purified water titanium dioxide - tenofovir disoproxil tablets in combination with other antiretroviral agents are indicated for the treatment of hiv-infected adults and paediatric patients 12 years of age and older.

Ирландия - английский - HPRA (Health Products Regulatory Authority)

rowex ltd - tenofovir disoproxil - film-coated tablet - 245 milligram(s) - nucleoside and nucleotide reverse transcriptase inhibitors; tenofovir disoproxil

Австралия - английский - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - emtricitabine, quantity: 200 mg; tenofovir disoproxil fumarate, quantity: 300 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; pregelatinised starch; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake - treatment of hiv-1 infection: cipla tenofovir + emtricitabine 300/200 is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents. pre-exposure prophylaxis: cipla tenofovir + emtricitabine 300/200 is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples.

Ирландия - английский - HPRA (Health Products Regulatory Authority)

teva b.v. - tenofovir disoproxil - film-coated tablet - 245 milligram(s) - nucleoside and nucleotide reverse transcriptase inhibitors; tenofovir disoproxil

Ирландия - английский - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - tenofovir disoproxil - film-coated tablet - 245 milligram(s) - nucleoside and nucleotide reverse transcriptase inhibitors; tenofovir disoproxil

Соединенные Штаты - английский - NLM (National Library of Medicine)

janssen products lp - darunavir (unii: yo603y8113) (darunavir - unii:yo603y8113), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir alafenamide (unii: el9943ag5j) (tenofovir anhydrous - unii:w4hfe001u5) - symtuza is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and pediatric patients weighing at least 40 kg: - who have no prior antiretroviral treatment history or - who are virologically suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir. darunavir and cobicistat are both inhibitors of the cytochrome p450 3a (cyp3a) isoform. symtuza should not be co-administered with medicinal products that are highly dependent on cyp3a for clearance and for which increased plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). darunavir and cobicistat are both substrates of the cytochrome p450 3a (cyp3a) isoform. co-administration of symtuza with cyp3a inducers is expected to lower plasma concentrations of darunavir and cobicistat which may lead to loss of efficacy

Уганда - английский - National Drug Authority

hetero labs ltd - tenofovir alafenamide hemifumarate - oral solid ordinary film-coated tablets - 25mg